IRVINGTON, New York--Electro-Optical Sciences, Inc. has announced it has signed an exclusive licensing agreement with KaVo Dental GmbH to further develop and commercialize DIFOTI, a U.S. Food and Drug Administration-cleared non-invasive imaging device developed by EOS for the detection of dental caries.
In accordance with the terms of the agreement, KaVo will pay EOS an undisclosed upfront sum as well as up to a double digit annual royalty based on the number of systems sold per calendar year. KaVo, a leading dental equipment manufacturer, has made a multi-million dollar commitment to refine the DIFOTI product for commercial launch.
"We are excited to add DIFOTI to our product portfolio. DIFOTI presents an ideal addition to our strategy for prophylactic and minimal invasive technologies. It visualizes dental caries, or tooth decay in an X-Ray-like image without exposing the patient to radiation--with a sensitivity of up to 10 times. We believe it will enable dentists to improve and accelerate diagnosis. It supports therefore the current trend towards Minimally Invasive Dentistry and fits very well with our other products in the portfolio," said Michael Eidenschink, Business Unit Director of KaVo's High Tech Business Unit.
"We are pleased that KaVo will be commercializing DIFOTI to realize its true value in the high-tech dental arena. KaVo is known for its constant innovation and we believe that their marketing expertise will allow for tremendous success with DIFOTI," said Joseph V. Gulfo, MD, MBA, president and CEO of EOS. "EOS remains focused on the development and commercialization of MelaFind, our non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma."
